Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Neth J Med ; 76(1): 14-26, 2018 01.
Article in English | MEDLINE | ID: mdl-29380728

ABSTRACT

BACKGROUND: While conversion from cyclosporine to everolimus is well documented, conversion from tacrolimus has been poorly studied. In this randomised, controlled trial the safety and tolerability of switching from tacrolimus to everolimus with glucocorticoid withdrawal after living-donor kidney transplantation was studied. METHODS: A total of 194 patients were planned to be randomised 1:1 to either continue tacrolimus or to convert to everolimus at month 3 after transplantation. At randomisation, all patients received tacrolimus, mycophenolate mofetil and prednisolone. Everolimus was started in a dose of 1.5 mg twice daily, aiming for predose concentrations of 4-7 ng/ml. Prednisolone was gradually withdrawn in both groups. RESULTS: The trial was stopped prematurely after the inclusion of 60 patients. The interim analysis showed an unacceptably high rejection rate in the everolimus group as compared with the control group: 30.0% vs. 6.7% (95% CI: 0.047-0.420; p = 0.045). An additional 8 patients stopped everolimus because of toxicity. At the end of follow-up (month 12) only 12 (40%) patients assigned to everolimus were still on the study drug. CONCLUSIONS: Conversion from tacrolimus to everolimusbased immunosuppression with withdrawal of prednisolone three months after kidney transplantation results in an unacceptably high risk of acute rejection and causes considerable toxicity. Based on our findings, such a switch strategy cannot be recommended.


Subject(s)
Drug Substitution/adverse effects , Everolimus/administration & dosage , Glucocorticoids/administration & dosage , Graft Rejection/chemically induced , Immunosuppressive Agents/administration & dosage , Kidney Transplantation , Tacrolimus/administration & dosage , Adult , Aged , Female , Humans , Living Donors , Male , Middle Aged , Postoperative Period , Prospective Studies , Treatment Outcome
2.
Am J Transplant ; 16(7): 2085-96, 2016 07.
Article in English | MEDLINE | ID: mdl-26714287

ABSTRACT

Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose to achieve therapeutic exposure compared with nonexpressers. This randomized-controlled study investigated whether adaptation of the tacrolimus starting dose according to CYP3A5 genotype increases the proportion of kidney transplant recipients being within the target tacrolimus predose concentration range (10-15 ng/mL) at first steady-state. Two hundred forty living-donor, renal transplant recipients were assigned to either receive a standard, body-weight-based or a CYP3A5 genotype-based tacrolimus starting dose. At day 3, no difference in the proportion of patients having a tacrolimus exposure within the target range was observed between the standard-dose and genotype-based groups: 37.4% versus 35.6%, respectively; p = 0.79. The proportion of patients with a subtherapeutic (i.e. <10 ng/mL) or a supratherapeutic (i.e. >15 ng/mL) Tac predose concentration in the two groups was also not significantly different. The incidence of acute rejection was comparable between both groups (p = 0.82). Pharmacogenetic adaptation of the tacrolimus starting dose does not increase the number of patients having therapeutic tacrolimus exposure early after transplantation and does not lead to improved clinical outcome in a low immunological risk population.


Subject(s)
Body Weight , Cytochrome P-450 CYP3A/genetics , Graft Rejection/genetics , Kidney Failure, Chronic/surgery , Kidney Transplantation , Living Donors , Tacrolimus/therapeutic use , Adult , Aged , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Genotype , Glomerular Filtration Rate , Graft Rejection/drug therapy , Graft Rejection/epidemiology , Graft Survival/drug effects , Humans , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/genetics , Kidney Function Tests , Male , Middle Aged , Netherlands/epidemiology , Polymorphism, Single Nucleotide , Postoperative Complications , Prevalence , Prognosis , Prospective Studies , Risk Factors , Young Adult
3.
Clin Exp Immunol ; 180(2): 329-40, 2015 May.
Article in English | MEDLINE | ID: mdl-25557528

ABSTRACT

Memory B cells play a pivotal role in alloreactivity in kidney transplantation. Follicular T helper (Tfh) cells play an important role in the differentiation of B cells into immunoglobulin-producing plasmablasts [through interleukin (IL)-21]. It is unclear to what extent this T cell subset regulates humoral alloreactivity in kidney transplant patients, therefore we investigated the absolute numbers and function of peripheral Tfh cells (CD4(POS) CXCR5(POS) T cells) in patients before and after transplantation. In addition, we studied their relationship with the presence of donor-specific anti-human leucocyte antigen (HLA) antibodies (DSA), and the presence of Tfh cells in rejection biopsies. After transplantation peripheral Tfh cell numbers remained stable, while their IL-21-producing capacity decreased under immunosuppression. When isolated after transplantation, peripheral Tfh cells still had the capacity to induce B cell differentiation and immunoglobulin production, which could be inhibited by an IL-21-receptor-antagonist. After transplantation the quantity of Tfh cells was the highest in patients with pre-existent DSA. In kidney biopsies taken during rejection, Tfh cells co-localized with B cells and immunoglobulins in follicular-like structures. Our data on Tfh cells in kidney transplantation demonstrate that Tfh cells may mediate humoral alloreactivity, which is also seen in the immunosuppressed milieu.


Subject(s)
B-Lymphocytes/immunology , Graft Rejection/immunology , Immunity, Humoral , Immunologic Memory , Kidney Transplantation , T-Lymphocytes, Helper-Inducer/immunology , Adult , Aged , B-Lymphocytes/physiology , Cell Line , Female , Graft Rejection/pathology , Graft Rejection/prevention & control , Humans , Immunosuppression Therapy/methods , Interleukins/immunology , Male , Middle Aged , T-Lymphocytes, Helper-Inducer/pathology
5.
Am J Transplant ; 13(5): 1253-61, 2013 May.
Article in English | MEDLINE | ID: mdl-23480233

ABSTRACT

Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the concentration-effect relationship for Tac is poorly defined. This study investigated whether Tac concentrations are associated with acute rejection in kidney transplant recipients. Data from three large trials were pooled. We used univariate and multivariate analysis to investigate the relationship between biopsy-proven acute rejection (BPAR) and Tac predose concentration at five time points (day 3, 10 and 14, and month 1 and 6 after transplantation). A total of 136/1304 patients experienced BPAR, giving an overall incidence of 10.4%. We did not find any significant correlations between Tac predose concentrations and the incidence of BPAR at the different time points. In the multivariate analysis, only delayed graft function (DGF) and the use of induction therapy were independently correlated with BPAR, with an odds ratio of 2.7 [95% CI: 1.8-4.0; p < 0.001] for DGF and 0.66 [95% CI: 0.44-0.99; p = 0.049] for induction therapy. The other variables, including the Tac predose concentrations, were not statistically significantly associated with BPAR. We did not find an association between the Tac predose concentrations measured at five time points after kidney transplantation and the incidence of acute rejection occurring thereafter. Based on this study it is not possible to define the optimal target concentrations for Tac.


Subject(s)
Graft Rejection/metabolism , Kidney Transplantation , Tacrolimus/pharmacokinetics , Acute Disease , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Graft Rejection/drug therapy , Graft Rejection/epidemiology , Humans , Immunosuppressive Agents/administration & dosage , Incidence , Male , Middle Aged , Netherlands/epidemiology , Prognosis , Tacrolimus/administration & dosage , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...